Drug Database
IV

IVIG (Privigen / IVIG, liquid, CSL / IgPro10)

✓ Approved

CSL Behring · Polyclonal Antibodies · Polyclonal Antibodies

What is IVIG?

IVIG is a polyclonal antibodies developed by CSL Behring. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesPrivigen, IVIG, liquid, CSL, IgPro10
CompanyCSL Behring
Drug ClassPolyclonal Antibodies, Antibody
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, CSL Behring

Therapeutic Indications

IVIG is developed for 9 unique indications across 6 therapeutic areas.

Therapeutic AreaConditionPhase
Skin and subcutaneous tissue disordersPurpura✓ Approved
Immune system disordersImmunodeficiency✓ Approved
Nervous system disordersMultifocal motor neuropathy✓ Approved
Musculoskeletal and connective tissue disordersScleroderma✓ Approved
Nervous system disordersGuillain-Barre syndrome✓ Approved

+4 more indications available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedClinical pediatrics2026-08-25

Successful Therapy of CNS Tuberculosis With Granulomatous Inflammation in Immunodeficiency.

Cagdas Deniz D, Gocmen Rahsan R, Sonmez Gamze G, Akarsu Aysegul A et al.

Central nervous system (CNS) tuberculosis (TB) carries high mortality and neurologic sequelae, especially when unrecognized inborn errors of immunity are present. We report a young woman with refractory TB meningitis, multiple intracranial tuberculomas, hydrocephalus, and intracranial hypertension despite 10 months of standard anti-TB therapy and corticosteroids. Severe vomiting led to poor adherence and severe weight loss. As immunologic evaluation suggested atypical combined immunodeficiency (CID); monthly intravenous immunoglobulin (IVIG) was started. Neurosurgery did not give indication for shunt surgery. Given the severity and presumed impaired antimycobacterial immunity, adjuvant interferon-γ (IFN-γ; 50 µg/m² 3 times weekly) was added to therapy with steroids. Vomiting resolved, weight improved, and treatment was tolerated. Serial magnetic resonance imaging showed reduction in leptomeningeal enhancement and tuberculoma burden without surgery; no neurologic sequelae developed. Next-generation sequencing identified a homozygous NHEJ1 variant, not confirmed by Sanger, but findings supported CID. In refractory CNS-TB with suspected immunodeficiency, IFN-γ, steroids, IVIG in addition to anti-TB therapy may improve outcomes and avoid neurosurgical intervention. Early immunological evaluation and host-directed therapy should be considered.

PMID 42638394
Read full article →
PubMedCureus2026-08-25

A Recurrent and Atypical Form of Guillain-Barré Syndrome: A Case Report.

Ed Dafali Larbi L, Semlali Shaimae S, Lachraf Hind H, Elharrak Saad S et al.

Guillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy characterized by rapidly progressive sensorimotor impairment that is classically ascending and monophasic. Recurrent and descending forms are rare and may complicate diagnosis. We report an atypical recurrent case of GBS in a child presenting with descending paralysis. We describe a nine-year-old girl with a history of typical GBS who was admitted to the pediatric ICU for acute descending flaccid paralysis. The clinical course rapidly progressed to tetraplegia with bulbar and respiratory involvement. Electroneuromyography showed acute demyelinating motor polyneuropathy, CSF analysis revealed albuminocytologic dissociation, spinal MRI demonstrated cauda equina nerve root enhancement, and anti-ganglioside antibodies were positive. The patient required mechanical ventilation and multiple courses of IVIG, with subsequent significant neurological recovery and complete remission at three months. Recurrent GBS is rare. Descending paralysis is atypical in this disease and may delay diagnosis. In such cases, repeated clinical evaluation and supportive paraclinical investigations are essential. The benefit of repeated courses of IVIG in poorly responsive cases remains uncertain and is supported by limited evidence. This case highlights the importance of considering GBS in acute flaccid paralysis, even in atypical and recurrent presentations, and underscores the diagnostic value of paraclinical investigations in such contexts.

PMID 42639621
Read full article →
PubMedImmunotherapy2026-08-25

Low-dose interleukin-2 combined with thalidomide for a severe cutaneous immune-related adverse event associated with PD-1/CTLA-4 bispecific antibody therapy: a case report.

Li Zhiqiang Z, Li Yufei Y, Zhang Yuhan Y, Ye Qiuxia Q et al.

Immune checkpoint inhibitors (ICIs), including novel bispecific antibodies targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have expanded therapeutic options but have also increased the incidence and complexity of immune-related adverse events (irAEs). Low-dose interleukin-2 (Ld-IL2) has been explored as a potential immunomodulatory strategy. However, its role in real-world combination regimens for managing severe cutaneous irAEs remains to be fully elucidated. We report the case of a patient with gastric cancer who developed rapidly progressive erythema and pruritus after treatment with iparomlimab and tuvonralimab. Symptoms worsened despite corticosteroids, intravenous immunoglobulin (IVIG) and antihistamines. After Ld-IL2 and thalidomide were added while corticosteroid treatment was continued, clinical improvement was observed within 48 hours, with complete resolution of the skin lesions at 2 weeks. Because Ld-IL2, thalidomide, and corticosteroids were administered concurrently, the independent contribution of each treatment and the underlying immunological mechanism could not be determined. However, further studies are warranted to clarify the potential value of this combined regimen in the management of such adverse events.

PMID 42639811
Read full article →
PubMedFrontiers in oncology2026-08-25

Liquid biopsies for detection, characterization, and interception of therapy resistance in thoracic malignancies.

Oner Ezgi E, M Saini Volga V, Cahill Christina C, O'Toole Hannah H et al.

Therapy resistance remains a leading cause of treatment failure and mortality in thoracic malignancies, despite major advances in targeted therapies and immunotherapies. Resistance evolves through heterogeneous, patient-specific mechanisms, including genetic alterations, epigenetic reprogramming, lineage plasticity, and tumor-microenvironment interactions, often emerging before radiographic progression or clinical relapse. Conventional tissue biopsies and imaging, while essential for diagnosis and treatment selection, are limited in their ability to capture spatial and temporal tumor heterogeneity or to support dynamic monitoring of tumor evolution. Liquid biopsy has therefore emerged as a minimally invasive approach for real-time assessment of tumor-derived biomarkers in circulation, enabling longitudinal tracking of resistance biology across the cancer care continuum. In this review, we highlight recent advances in liquid biopsy applications for thoracic malignancies, focusing on circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) as complementary analytes for baseline molecular profiling, detection of primary and acquired resistance to therapy, and identification of minimal residual disease and molecular relapse. Beyond mutation-based approaches, we highlight emerging non-genomic ctDNA features, including epigenomic and fragmentomic signatures, that capture treatment-induced adaptation and lineage plasticity not detectable by conventional plasma genomic profiling, and discuss advances in CTC technologies that preserve cellular and phenotypic context relevant to resistance and metastatic potential. Finally, we examine multimodal liquid biopsy strategies that integrate multiple circulating analytes with artificial intelligence-assisted methods to enhance sensitivity, provide a more comprehensive view of tumor biology, and inform adaptive therapy strategies. We also outline key analytical and clinical challenges that must be addressed through standardized, prospective trials to translate liquid biopsy-guided surveillance and early interception of resistance into improved patient outcomes.

PMID 42639369
Read full article →
PubMedThe journal of physical chemistry. C, Nanomaterials and interfaces2026-08-25

Reaction of a Laser-Ablated Al Plume with a Fluorinated Ionic-Liquid Surface: Characterizing the AlF-Producing Species.

Pearcy Philip A J PAJ, Lane Paul D PD, Rubli Peter T PT, Haakansson Christian T CT et al.

The species present in a laser-ablated Al plume have been characterized and their reactivity with the surface of the ionic liquid, 1-ethyl-3-methylimidazolium bis-(trifluoromethylsulfonyl)-imide ([C2mim]-[Tf2N]), has been investigated. Al atoms were confirmed to be present and their kinetic-energy distributions determined by laser-induced fluorescence time-of-flight measurements, over a wider range of ablation fluences than reported previously. Cations were detected directly using an in-line microchannel-plate-detector assembly. Corroboratory measurements of the ions entrained in a He buffer gas confirmed Al+ to be the only cation present in measurable concentrations. The Al+ kinetic energies were determined by time-of-flight and found to be much hotter than anticipated based on previous independent reports; under the highest-fluence conditions examined (30 mJ pulse-1, nominal fluence of 42 J cm-2), the mean kinetic energies of Al and Al+ were 17 and 450 eV, respectively. Using an electrostatic deflector, it was shown that both Al and Al+ projectiles produce AlF through reaction at the surface of the ionic liquid [C2mim]-[Tf2N] containing a fluorinated anion. The AlF yield from Al+ is mildly dominant under our conditions. AlF leaves the surface with near-thermal kinetic energy and rotational distributions. There is a minor component of vibrationally excited AlF which is confined to the fastest products. The observation of near-complete thermalization of the AlF products is consistent with significant penetration of the projectiles into the liquid, as would be anticipated from the high incident kinetic energies, particularly for Al+. The results provide new insights into reactive-atom scattering (RAS) from fluorine-containing liquid surfaces.

PMID 42639506
Read full article →
PubMedScientific reports2026-08-25

Re-engineering alum sludge using choline-glycine ionic liquid for enhanced dewatering and dye adsorption in wastewater treatment.

Rashed Aya M AM, El-Sayed Ibrahim E T IET, Lu Xingmei X, Abdel-Bary Hamed M HM et al.

Large quantities of by-product alum sludge (Al-S) generated from drinking water treatment plants pose significant environmental and disposal challenges due to their high water content and large volume. This study aims to develop a sustainable conditioning and valorization strategy for Al-S using a choline-glycine ionic liquid ([Ch]-[AA]). The ionic liquid was synthesized and applied as a sludge conditioner to enhance dewatering performance. Under optimized conditions, the dewatering efficiency reached 47%, accompanied by a notable zeta potential shift, indicating partial charge neutralization and improved floc structure. To enable sludge valorization, the conditioned sludge was reused as an adsorbent, either directly or after thermal treatment. The modified materials exhibited high adsorption capacities toward Synozol KHL dyes, reaching 43.6 and 90.1 mg g⁻1 for Red and Blue dyes, respectively. Adsorption behavior was well described by the Langmuir isotherm and pseudo-second-order kinetic model. Thermodynamic analysis indicated an exothermic adsorption process, with spontaneity dependent on operating conditions. Overall, the results demonstrate an effective waste-to-resource approach in which enhanced dewatering facilitates the conversion of alum sludge into a functional adsorbent for wastewater treatment, supporting sustainable sludge management.

PMID 42637886
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about IVIG